

Aelis Farma will participate in the Addiction 2022 conference dedicated to innovation in the treatment of addictions

Bordeaux, September 22, 2022 - 6:00 p.m. CEST - Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its participation as a speaker at the [Addiction 2022](#) international conference to be held from September 25 to 28, 2022 in Sardinia, Italy.

Pier Vincenzo Piazza, CEO of Aelis Farma, will give the opening plenary lecture of the *Addiction 2022* conference on September 26, 2022. The title of the lecture is "Dangerous Liaisons: How a general theory of addiction engendered a new class of drugs". The presentation will focus on the discovery, mechanism of action and effects of the new pharmacological class developed by Aelis Farma, CB₁-SSi, and more specifically on the first drug candidate of this class, AEF0117, which targets disorders related to excessive cannabis use (addiction and psychosis).

"That is an honor to be invited by the international scientific community in the field of addiction to give this plenary lecture. We are very proud to present our new pharmacological class, CB₁-SSi, and our most advanced drug candidate, AEF0117, to such a prestigious group of scientists who are showing their interest in the new class of drugs developed by Aelis Farma and more generally in cannabis addiction. AEF0117 has shown indications of efficacy in a phase 2a study and has entered a phase 2b study with a larger population in the United States, a country particularly affected by this type of addiction," said **Pier Vincenzo Piazza**.

About AELIS FARMA

Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB₁ receptor of the endocannabinoid system (CB₁-SSi). These new molecular entities hold great potential in the treatment of many brain diseases. CB₁-SSi were developed by Aelis Farma on the basis of the discovery of a new natural defense mechanism of the brain made by the team of Dr. Pier Vincenzo Piazza, CEO of the Company, when he was Director of the Inserm Magendie Neurocenter in Bordeaux. For these discoveries, Dr. Piazza was awarded the Inserm Grand Prix and the Grand Prix of Neurology of the French Academy of Sciences, which are among the most prestigious French prizes in medicine and neurology.

Aelis Farma is developing two first-in-class drug candidates that are at the clinical stage, AEF0117 and AEF0217, and has a portfolio of innovative CB₁-SSi for the treatment of other diseases associated with a dysregulation of the activity of the CB₁ receptor.

AEF0117, which targets the disorders due to excessive cannabis use (addiction and psychosis), has shown indications of efficacy in a phase 2a clinical trial and has entered a phase 2b clinical trial in the United States in the second quarter 2022. Aelis Farma has an exclusive option-license agreement with Indivior PLC, a leading pharmaceutical company in the treatment of addiction, for the development and commercialization of AEF0117 for disorders due to excessive cannabis use. As part of this agreement, Aelis Farma received \$30 million (option payment). If Indivior exercises the license option at the end of the phase 2b, Aelis Farma will receive a \$100 million license fee (potentially in 2024) and up to \$340 million in additional payments

contingent on the achievement of development, regulatory and commercial milestones as well as, royalties on net sales of AEF0117 ranging between 12% and 20%.

AEF0217, which targets various cognitive disorders including those associated with Down syndrome, has finished recruitments of its phase 1 program in healthy volunteers and will start in the fourth quarter 2022 a phase 1/2 study in Down syndrome subjects. This compound has undergone an extensive preclinical proof-of-concept program using highly innovative assessing cognitive functions. In this context, AEF0217 has demonstrated its ability to completely reverse cognitive deficits observed in several animal models of neurodevelopmental disorders, such as Down syndrome and Fragile X syndrome, as well as in models of certain cognitive deficits associated with aging.

Based in Bordeaux, within the Magendie Neurocenter, Aelis Farma has a team of 23 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aequi-invest and IRDI Capital Investissement.

For more information: www.aelisfarma.com



ISIN: FR0014007ZB4

Ticker: AELIS

B Compartment of Euronext Paris

Contacts

AELIS FARMA

Pier Vincenzo Piazza

CEO

contact@aelisfarma.com

NewCap

Dusan Oresansky/Hugo Willefert

Investor Relations

aelis@newcap.eu

+33 1 44 71 94 92

NewCap

Arthur Rouillé

Relations médias

aelis@newcap.eu

+33 1 44 71 00 15

Disclaimer

Forward-looking statements

Some information contained in this press release are forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance or achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and detailed in Chapter 3 "Risk Factors" of Aelis Farma's registration document approved by the Autorité des marchés financiers on 14 January 2022 under number I.22-003.

These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.